Physiomics plc (AIM: PYC) announced on Monday that it has secured a contract with a UK-based biotech company developing antibody-drug conjugate (ADC) therapies for hard-to-treat cancers.
The GBP102,000 project will run from April to August 2025 and focus on developing a pharmacokinetic (PK) and pharmacodynamic (PD) model to optimise dosing for the client's First-in-Human trial.
As a leader in mathematical modelling, data science and biostatistics, Physiomics supports biotech and pharma firms in streamlining drug development.
Leveraging its proprietary Virtual Tumour technology and computational expertise, the company has contributed to over 100 commercial projects, collaborating with clients such as Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics and Cancer Research UK.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA